3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
4
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Waldenstrom Macroglobulinemia
1
Solid Tumor
1
Skin Neoplasms
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intraocular Lymphoma
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Interventions
vistusertib
2
toripalimab
1
tislelizumab
1
tanespimycin
1
sargramostim
1
roniciclib
1
abemaciclib
1
Letrozole
1
Ipilimumab
1
Hydroxychloroquine
1
Fulvestrant
1
Anastrozole
1
Albumin-Bound Paclitaxel
1
AMG 337
1
4-toluenesulfonamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Solid Tumor
×
sargramostim
×
Clear all
NCT05284214
2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2
Withdrawn